NanoViricides, Inc. (NNVC)

NYSEAMERICAN: NNVC · IEX Real-Time Price · USD
1.46
+0.01 (0.69%)
Jan 27, 2023, 3:46 PM EST - Market closed
0.69%
Market Cap 16.95M
Revenue (ttm) n/a
Net Income (ttm) -7.06M
Shares Out 11.61M
EPS (ttm) -0.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 10,416
Open 1.47
Previous Close 1.45
Day's Range 1.43 - 1.47
52-Week Range 1.04 - 3.88
Beta 1.07
Analysts Buy
Price Target 8.67 (+493.84%)
Earnings Date Feb 13, 2023

About NNVC

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-In... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Dr. Anil R. Diwan Ph.D.
Employees 17
Stock Exchange NYSEAMERICAN
Ticker Symbol NNVC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for NNVC stock is "Buy." The 12-month stock price forecast is $8.67, which is an increase of 493.84% from the latest price.

Price Target
$8.67
(493.84% upside)
Analyst Consensus: Buy
Stock Forecasts

News

NanoViricides, Inc. to Present at the Biotech Showcase(TM) 2023 Conference in San Fransisco on January 9th at 10:30am PT

SHELTON, CT / ACCESSWIRE / January 4, 2023 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), announces that the Company's President, Dr. Anil Diwan, will be presenting a talk in person at the B...

3 weeks ago - Accesswire

NanoViricides, Inc. to Present at the RHK Capital Disruptive Growth Conference in New York City on December 6th at 1:20pm ET

SHELTON, CT / ACCESSWIRE / December 5, 2022 / NanoViricides, Inc. (NYSE Amer. NNVC) (the "Company"), announces that the Company's President, Dr. Anil Diwan, will be presenting a talk at the RHK Capita...

1 month ago - Accesswire

NanoViricides, Inc. Has Filed its Quarterly Report: Coronavirus Drug NV-CoV-2 IND Stage

SHELTON, CT / ACCESSWIRE / November 15, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal first quarter ending...

2 months ago - Accesswire

7 Speculative Penny Stocks Under $3 That Deserve Your Attention in Nov.

Risk is part of investing. Even the most mature, well-established firms and stocks run the risk of declining to zero.

3 months ago - InvestorPlace

NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug NV-CoV-2 IND Stage

SHELTON, CT / ACCESSWIRE / October 14, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 202...

3 months ago - Accesswire

NanoViricides Provides Additional Details on Its Rapid Monkeypox Drug Strategy

SHELTON, CT / ACCESSWIRE / August 9, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in the development of highly effective antiviral therapies based on a novel nanome...

6 months ago - Accesswire

NanoViricides shares soar 41% after announcing plans to develop a monkeypox treatment

Shares of NanoViricides Inc. NNVC, +19.42% jumped 41.8% in premarket trading on Thursday after the company said it began developing a monkeypox treatment. There are currently no approved or authorized...

6 months ago - Market Watch

NanoViricides Reports That It Has Begun Drug Development to Combat Monkeypox Virus

SHELTON, CT / ACCESSWIRE / August 4, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in the development of highly effective antiviral therapies based on a novel nanome...

6 months ago - Accesswire

NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2022 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Progressing Further for Clinical Trials Application

SHELTON, CT / ACCESSWIRE / May 17, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedic...

9 months ago - Accesswire

NanoViricides Starts Drug Development Program For Recent Cases Of Unexplained Pediatric Hepatitis

NanoViricides Inc (NYSE: NNVC) has initiated a program to screen its library of broad-spectrum antiviral nanoviricides against human Adenovirus 41 Type F (hAd41-F), believed to be strongly associated ...

9 months ago - Benzinga

NanoViricides Reports that It Has Begun Drug Development to Combat Recent Cases of Severe Pediatric Hepatitis

SHELTON, CT / ACCESSWIRE / May 16, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedic...

9 months ago - Accesswire

NanoViricides Provides Update On NV-CoV-2 Coronavirus Drug Candidate Program

SHELTON, CT / ACCESSWIRE / April 25, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomed...

9 months ago - Accesswire

NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2021 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Clinical Trials Application Ready

SHELTON, CT / ACCESSWIRE / February 15, 2022 / NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nan...

1 year ago - Accesswire

NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards Clinical Trials

SHELTON, CT / ACCESSWIRE / November 16, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nano...

1 year ago - Accesswire

EXCLUSIVE: NanoViricides Completes Oral Gummies, Lung Inhalation Formulations For COVID-19 Treatment

NanoViricides, Inc. (NYSE: NNVC) announced Monday it has developed an oral gummies formulation of its COVID-19 Drug Candidate NV-CoV-2 to benefit non-hospitalized patients. The company believes the fo...

1 year ago - Benzinga

NanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2

SHELTON, CT / ACCESSWIRE / November 15, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedici...

1 year ago - Accesswire

NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug Program Rapidly Moving Towards Clinical Stage

SHELTON, CT / ACCESSWIRE / October 13, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 202...

1 year ago - Accesswire

NanoViricides: There Is More to Come

NanoViricides Inc. ( NNVC , Financial) is one of the emerging biotech companies that I have been following for a while now. Its stock price had more than doubled last month after a major update from t...

1 year ago - GuruFocus

NanoViricides COVID-19 Treatment Candidate Found Effective Against Coronavirus Variants In Lab Study

Shares of NanoViricides Inc (NYSE: NNVC), a developer of antiviral therapies based on a novel nanomedicines technology, are higher Monday. What Happened: NanoViricides said its pan-Coronavirus COVID-1...

1 year ago - Benzinga

NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus Activity

Shelton, Connecticut -- (October 11, 2021) - NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicin...

1 year ago - Benzinga

NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus Activity.

SHELTON, CT / ACCESSWIRE / October 11, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicin...

1 year ago - Accesswire

NanoViricides Leaps Forward in its Quest to Defeat COVID-19

Photo by Louis Reed on Unsplash Since the coronavirus pandemic started, scientists have worked to develop a vaccine to inoculate the population and stop the spread of COVID-19. The good news is they s...

1 year ago - Benzinga

NanoViricides: Why Has the Stock Doubled?

There were a large number of pharma companies of all sizes that began their research on developing both drugs as well as vaccines to counter the SARS-CoV-2 since 2019. Some of these companies have suc...

1 year ago - GuruFocus

Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral Drug

SHELTON, Conn., Sept. 22, 2021 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedic...

1 year ago - PRNewsWire

NNVC Stock: What Is Going on With Red-Hot NanoViricides Today?

A Covid-19 treatment producer halted trading this morning, but news has revealed that NNVC stock is still moving upward. The post NNVC Stock: What Is Going on With Red-Hot NanoViricides Today?

1 year ago - InvestorPlace